# PECS-2 for Breast Surgery

> **NCT03117894** · NA · COMPLETED · sponsor: **Umeå University** · enrollment: 200 (actual)

## Conditions studied

- Breast Neoplasm Female
- Regional Anesthesia
- Anesthesia
- Regional Anesthesia Morbidity
- Anesthesia Morbidity

## Interventions

- **DRUG:** Ropivacaine 5 mg/ml, 35 ml
- **DRUG:** Remifentanil 50 microg/ml
- **DRUG:** Betamethason 4 mg
- **DRUG:** Paracetamol 1,5 g
- **DRUG:** Propofol
- **DRUG:** Arcoxia, 120 mg
- **DRUG:** Ondansetron 4 mg
- **DRUG:** Morphine

## Key facts

- **NCT ID:** NCT03117894
- **Lead sponsor:** Umeå University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-23
- **Primary completion:** 2020-10-22
- **Final completion:** 2020-10-22
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2021-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03117894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03117894, "PECS-2 for Breast Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03117894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*